GSK2879552治疗复发/难治性小细胞肺癌的I期剂量递增研究
这项首次人体I期多中心开放标签研究评估了LSD1抑制剂GSK2879552在复发/难治性小细胞肺癌患者中的安全性、药代动力学、药效动力学和临床活性。29例患者入组9个剂量队列,常见治疗相关不良事件为血小板减少(41%),药代动力学良好但疾病控制差且不良事件率高,研究因风险获益比不利而终止。
要点
- GSK2879552在复发/难治性SCLC中疾病控制差且不良事件率高。
- 最常见治疗相关不良事件为血小板减少(12/29,41%)。
- 研究因风险获益比不利而终止,Part 2未进行。
核心结论
- GSK2879552是强效选择性LSD1抑制剂,药代动力学良好,但在SCLC中疾病控制差且不良事件率高,风险获益比不利导致研究终止。
研究设计与样本
- I期多中心开放标签首次人体研究(NCT02034123),纳入≥18岁复发/难治性SCLC患者,Part 1剂量递增,Part 2剂量扩展(未进行)。
- 2014年2月4日至2017年4月18日共29例患者分配至9个剂量队列(0.25 mg–3 mg每日一次及3 mg或4 mg间歇给药)。
主要发现
- 24/29(83%)患者发生至少1例治疗相关不良事件,最常见为血小板减少(12/29,41%)。
- 9例患者报告12例严重不良事件,其中6例治疗相关,最常见为脑病(4例SAE)。
- 3例患者死亡,1例死亡与SAE相关。
- 药代动力学特征为快速吸收、缓慢消除、暴露量随剂量成比例增加。
局限性
- Part 2剂量扩展未进行,样本量仅29例。
- 研究因风险获益比不利而终止,未确定推荐剂量和方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: This first-time-in-humans study assessed the safety, pharmacokinetics (PK), pharmacodynamics (PD), and clinical activity of GSK2879552 in patients with relapsed or refractory SCLC. METHODS: This phase I, multicenter, open-label study (NCT02034123) enrolled patients (≥18 years old) with relapsed or refractory SCLC (after ≥1 platinum-containing chemotherapy or refusal of standard therapy). Part 1 was a dose-escalation study; Part 2 was a dose-expansion study. Dose escalations were based on safety, PK, and PD. The primary end point (Part 1) was to determine the safety, tolerability, and recommended dose and regimen of GSK2879552. Secondary end points were to characterize PK and PD parameters and measure disease control rate at week 16. Part 2 was not conducted. RESULTS: Between February 4, 2014, and April 18, 2017, a total of 29 patients were allocated to one of nine dose cohorts (0.25 mg-3 mg once daily and 3-mg or 4-mg intermittent dosing). In all, 22 patients completed the study; 7 withdrew, primarily owing to adverse events (AEs). Most patients (24 of 29 [83%]) had at least one treatment-related AE, most commonly thrombocytopenia (12 of 29 [41%]). Twelve serious AEs (SAEs) were reported by nine patients; six were considered treatment related, the most common of which was encephalopathy (four SAEs). Three patients died; one death was related to SAEs. PK was characterized by rapid absorption, slow elimination, and a dose-proportional increase in exposure. CONCLUSIONS: GSK2879552 is a potent, selective inhibitor of lysine demethylase 1A and has demonstrated favorable PK properties but provided poor disease control and a high AE rate in patients with SCLC. The study was terminated, as the risk-benefit profile did not favor continuation.
引用
- Bauer TM, Besse B, Martinez-Marti A, et al. Phase I, Open-Label, Dose-Escalation Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of GSK2879552 in Relapsed/Refractory SCLC. J Thorac Oncol. 2019. PMID: 31260835. doi:10.1016/j.jtho.2019.06.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。